 |
 |
Argeris N. Karabelas, Ph.D.
Director
Dr. Argeris ("Jerry") Karabelas co-founded Vanda with Dr. Polymeropoulos in 2003. He served as Chairman of the Board from 2003 to December 2010. Jerry currently serves as a Director of Vanda. He is a Partner at Care Capital, a life sciences venture capital firm with $500 million under management. Jerry currently serves as Chairman of the Board for several of Care Capital's portfolio companies, including Cyreniac Pharmaceuticals. Jerry also serves as a Director for Inotek Pharmaceuticals and NormOxys, Inc. In addition to these board positions, Jerry also serves as Chairman of Human Genome Sciences. He has previously served on the board of several other companies, including Renovo, Anadys Pharmaceuticals, Acura Pharmaceuticals, SkyePharma plc, Nitromed, Minster Pharmaceuticals, and the Fox Chase Cancer Center.
Prior to Care Capital, Jerry was the Founder and Chairman of the Novartis BioVenture Fund. In this role he invested approximately $40 million in 14 portfolio companies including Eyetech, Indenix and Theravance. From 1998 to 2000, Jerry was Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG. He had full responsibility for Novartis Pharma, Ciba Vision and Generics representing $12 billion in annual sales. Included in these responsibilities was strategic and operational leadership of R&D with a budget in excess of $2 billion. Prior to joining Novartis, Jerry was Executive Vice President of SmithKline Beecham responsible for US operations, European operations, Regulatory, and Strategic Marketing. He has been responsible for numerous pharmaceutical product approvals and new product launches, including the launch of four $1 billion products.
Jerry holds a Ph.D. in Pharmacokinetics from the Massachusetts College of Pharmacy and a BS in Biochemistry from UNH. He is a member of the Visiting Committee for Health Sciences and Technology at MIT and past member of Scientific Advisory Committee of Mass General Hospital.
 |
 |